In detail, in NAFLD subjects, butyrate-producing probiotics reduce the accumulation of lipids in the liver by improving hepatic resistance to insulin through the activation of AMP-activated protein kinase (AMPK), and the expression of factor-related erythroid nuclear factor 2 2 (Nrf2) in rats with NAFLD. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.